Sparsentan has not been listed in Chinese Mainland and has not been included in the national medical insurance reimbursement. If patients need to use it, they need to purchase it through overseas channels, but special attention should be paid to risk factors such as drug authenticity and expiration date.

1. Listing status

(1) Domestic listing: As of September 2025, Sipasentan has not been approved for listing by the China National Medical Products Administration.

(2) Medical insurance coverage: Due to not being marketed domestically, this drug is not included in the Chinese medical insurance reimbursement catalog.

2 ways to obtain

(1) Overseas purchase: Patients can obtain it through compliant cross-border medical channels and must provide a formal prescription.

(2) Attention: It is necessary to verify the drug approval number, production batch number, and expiration date to avoid purchasing counterfeit and inferior products.

3 Risk Warning

(1) Medication safety: Drugs that have not been approved domestically may have unknown risks of adverse reactions.

(2) Legal risk: Individuals bringing unregistered drugs into the country without authorization may violate customs regulations.